webinar register page

Webinar banner
RedChip Investor Group Call with Aptorum Group (NASDAQ: APM)
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to developing and commercializing therapeutic assets to treat diseases with unmet medical needs. Aptorum's current drug pipeline includes indications in oncological diseases (including orphan oncology indications) and infectious diseases. The Company has completed two clinical trials in 2021 in respect of ALS-4 (MRSA) and SACT-1 (Neuroblastoma) small molecule drugs and the Company is currently preparing IND applications for the next phases of human clinical trials in the United States. The Company is preparing to launch a dietary supplement for women undergoing menopause and experiencing related symptoms, including osteoporosis. Targeting a global woman’s health supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to generate near-term revenue with significant long-term growth potential.


Webinar logo
* Required information


CEO and Executive Director @Aptorum Group Limited
Mr. Darren Lui is the Chief Executive Officer and Executive Director since June 2022. Before that, he was President and an Executive Director of Aptorum Group Limited. Mr. Lui was previously the founder, director and responsible officer of Varengold Capital Securities Limited and Varengold Capital Asset Management Limited in Hong Kong, with subsidiaries operating brokerage, asset management, and investment businesses in Asia established since January 2015. Prior to this, he was a Director within the Fixed Income Group of Barclays Capital, where he spent over nine years from September 2005 to February 2014 developing and establishing their London, Singapore and New York teams. From September 2002 to August 2005 he was qualified as a Chartered Accountant with Ernst & Young LLP (London), specializing in capital markets advisory. Mr. Lui graduated with First-Class Honors from Imperial College, London with a BSc degree in Biochemistry in June 2002. He is a Chartered Accountant (ICAS), accre